Evidence map›Paper›PMID 40396609›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2025

Identification of broad-spectrum M

Man Liu, Li Zhao, Xupeng Huang, Zhenhao Tang, Yihang Zhong, Mengrong Yan, Shun Liu, Shunjing Wang, Zeyun Sun, Zixuan Rao and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Man LiuDepartment of Infectious Diseases, The Key Laboratory of Advanced Interdisciplinary Studies, The First Affiliated Hospital, Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou, China.
Li ZhaoInnovative Center for Pathogen Research, Guangzhou National Laboratory, Guangzhou, China, China.
Xupeng HuangInnovative Center for Pathogen Research, Guangzhou National Laboratory, Guangzhou, China, China.
Zhenhao TangInnovative Center for Pathogen Research, Guangzhou National Laboratory, Guangzhou, China, China.
Yihang ZhongInnovative Center for Pathogen Research, Guangzhou National Laboratory, Guangzhou, China, China.
Mengrong YanInnovative Center for Pathogen Research, Guangzhou National Laboratory, Guangzhou, China, China.
Shun LiuInnovative Center for Pathogen Research, Guangzhou National Laboratory, Guangzhou, China, China.
Shunjing WangInnovative Center for Pathogen Research, Guangzhou National Laboratory, Guangzhou, China, China.
Zeyun SunInnovative Center for Pathogen Research, Guangzhou National Laboratory, Guangzhou, China, China.
Zixuan RaoInnovative Center for Pathogen Research, Guangzhou National Laboratory, Guangzhou, China, China.
Linyi YuInnovative Center for Pathogen Research, Guangzhou National Laboratory, Guangzhou, China, China.
Yuying FangDepartment of Infectious Diseases, The Key Laboratory of Advanced Interdisciplinary Studies, The First Affiliated Hospital, Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou, China.
Wei ZhangDepartment of Infectious Diseases, The Key Laboratory of Advanced Interdisciplinary Studies, The First Affiliated Hospital, Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou, China.
Hongbo ZhangBeijing StoneWise Technology Co. Ltd, Beijing, China.
Wei PengDepartment of Infectious Diseases, The Key Laboratory of Advanced Interdisciplinary Studies, The First Affiliated Hospital, Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic underscores the urgent need to develop broad-spectrum antivirals against coronaviruses (CoVs) to prepare for future outbreaks. In this study, we presented a systematic approach to developing broad-spectrum M

Indexed as

Antiviral AgentsCoronavirus 3C ProteasesSARS-CoV-2COVID-19COVID-19 Drug TreatmentCrystallography, X-RayDose-Response Relationship, DrugHumansMolecular StructureStructure-Activity RelationshipAntiviral AgentsCoronavirus 3C ProteasesBroad-spectrumconserved interactionsMpro inhibitors

Identifiers

PMID40396609
PMCPMC12096674

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.